View in EDS HTML Full Text PDF Full Text

Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial

Saved in:

Bibliographic Details
Title:	Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a ^99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial
Authors:	Hubalewska-Dydejczyk, Alicja¹ (AUTHOR), Decristoforo, Clemens² (AUTHOR), Mikolajczak, Renata³ (AUTHOR), Kolenc, Petra^4,5 (AUTHOR), Opalinska, Marta¹ (AUTHOR), Garnuszek, Piotr³ (AUTHOR), Skorkiewicz, Konrad⁶ (AUTHOR), Glowa, Bogusław⁷ (AUTHOR), Trofimiuk-Muldner, Malgorzata¹ (AUTHOR), Studen, Andrej⁸ (AUTHOR), Simoncic, Urban⁸ (AUTHOR), Rangger, Christine² (AUTHOR), di Santo, Gianpaolo² (AUTHOR), Fani, Melpomeni⁹ (AUTHOR), Virgolini, Irene² (AUTHOR), Lezaic, Luka^4,10 (AUTHOR) luka.lezaic@kclj.si
Source:	Journal of Nuclear Medicine. Jun2026, Vol. 67 Issue 6, p895-902. 8p.
Database:	Engineering Source
Full text is not displayed to guests. Login for full access.

Be the first to leave a comment!